Zero Candida Ltd (TSX-V:ZCT) announced that it has filed to list its shares on the TSX Venture Exchange following its acquisition of Zero Candida Ltd (TSX-V:ZCT). (ZC), an Israeli private company.

As part of the acquisition, the company underwent a name change, a share split, and issued additional shares and incentive stock options to ZC stakeholders, making Zero Candida Ltd. a wholly-owned subsidiary.

The technology company is developing an AI smart tampon-like device designed to treat Candidiasis and transfer medical information to health professionals via Wi-Fi.

CEO Eli Ben Haroosh believes the company’s new technology will be a game-changer in the field of women’s health.

“Zero Candida has the potential to become a technological leader and use its ground-breaking technology to expand boundaries of non-chemical candida treatment,” he said.

He highlighted the company’s goal to complete a preclinical study by June 2025 to be submitted to the US Food and Drug Administration (FDA).

“The company continues to develop a final prototype for human use and will complete it by Q1 2025,” Haroosh said.